Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > VA Governor Tim Kaine Available for Satellite Interview

Abstract:
WHAT:

Governor Tim Kaine will be available for satellite uplink interviews while attending the BIO 2008 International Convention. The Governor will be discussing Virginia's recent Achievements in the Life Sciences Industry.
Refer to the following bulleted list for further details.

WHEN:

Wednesday, June 18, 2008, 11:15 a.m. - Noon PDT (2:15 - 3:00 p.m. EDT)

WHERE:

Satellite Uplink/POTS Interviews from:

BIO TV Studios, San Diego Convention Center

BIO 2008 International Convention

WHO: Virginia Governor Tim Kaine

VA Governor Tim Kaine Available for Satellite Interview

San Diego, CA | Posted on June 15th, 2008

Recent Virginia Achievements in the Life Sciences Industry

* Howard Hughes Medical Institute's Janelia Farm Campus in Loudoun County, Virginia, opened in Fall 2006. The $500 million facility was created to pursue fundamental problems in basic biomedical research that are difficult to approach in academia or industry. Three hundred jobs were created as a result of the project.

* In May 2003, Boehringer Ingelheim Corporation expanded its manufacturing capacity at its subsidiary, Boehringer Ingelheim Chemicals, Inc. in the City of Petersburg, Virginia. The completion of all phases of the Petersburg expansion were projected to reach $260 million in new capital investment by 2011 with an overall increase in employment of 165.

* Philip Morris USA announced in April 2005 its plans to invest $300 million to open a Research and Technology Center in Virginia. The project will create 500 new jobs, including scientists, lab technicians and lab support. The center will allow the company to develop new technologies that improve the products it currently manufactures, and may lead to innovative new products.

* December 2006 announcement by SRI International to establish a Center for Advanced Drug Research in Virginia. The Center will partner with James Madison University and other Virginia institutions of higher education in its research efforts that, in addition to drug research, will delve into areas such as biothreats and homeland security, engineering, nanotechnology, energy and information technology. By the end of the first ten years of operation, the project will create more than 100 new jobs with an average annual compensation of $85,000.

* In June 2007, Merck & Co., Inc. announced its second Virginia expansion in six months, which involved a $193 million investment to expand its Elkton, Virginia, facility, further enhancing production capabilities for the pharmaceutical company's medicines and vaccines. In December 2006, Merck & Co., Inc. announced a $57 million investment to expand the role its Elkton facility plays in producing GARDASIL®, Merck's cervical cancer vaccine. The investment included construction of a new building and the installation of equipment for the purification process—a key stage in manufacturing the product. Merck also completed construction of a vaccine fermentation facility at Elkton, which will be used to support an earlier stage in the GARDASIL manufacturing process. Merck first expanded its facility in 2005 to undertake part of the manufacturing process for GARDASIL™.

* Bostwick Laboratories announced in July 2007 a $4.6 million investment to expand its Henrico County, Virginia, headquarters facility. The expansion will create 600 new jobs in the area of urologic disease research that will help improve the lives of Virginians and people around the world.

* Covance announced in November 2007 its new pharmaceutical research and development laboratory in Prince William County, Virginia. The company is investing about $175 million.

* Earlier this year, Barr Laboratories invested $62 million to expand production and packaging capacity at its facility in Bedford County, Virginia. In addition to enhancing its current product line, the expansion allows Barr to add equipment that will incorporate a new timed-released technology for solid dosage pharmaceuticals.

####

About Biotechnology Industry Organization (BIO)
BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events

BIO International Convention
June 17-20, 2008
San Diego, CA


Pacific Rim Summit on Industrial Biotechnology and Bioenergy
Sept. 10-12, 2008
Vancouver, BC


BIO Investor Forum 2008
October 29-31, 2008
San Francisco, CA


BIO-Europe 2008
November 17-19, 2008
Mannheim/Heidelberg, Germany

For more information, please click here

Contacts:
Biotechnology Industry Organization (BIO)
Paul Winters, 202-962-9237

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Events/Classes

A New Blue: Mysterious origin of the ribbontail ray’s electric blue spots revealed July 5th, 2024

Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

June Conference in Grenoble, France, to Explore Pathways to 6G Applications, Including ‘Internet of Senses’, Sustainability, Extended Reality & Digital Twin of Physical World: Organized by CEA-Leti, the Joint EuCNC and 6G Summit Sees Telecom Sector as an ‘Enabler for a Sustainabl June 1st, 2022

Nanobiotechnology

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project